• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Clearside Biomedical highlights preliminary data from retreatment trial

June 8, 2017 By Sarah Faulkner

Clearside BiomedicalClearside Biomedical (NSDQ:CLSD) touted preliminary data from a non-interventional and retrospective trial of patients who participated in the completed Phase II trial of CLS-TA for suprachoroidal administration.

Clearside’s formulation of triamcinolone acetonide, in combination with intravitreally administered Eylea, was evaluated as a treatment for macular edema associated with retinal vein occlusion.

The company’s Phase II Tanzanite trial enrolled 46 treatment-naïve patients with RVO and included a branch of patients who received CLS-TA and intravitreal Eylea and a control arm of patients receiving only intravitreal Eylea.

Clearside previously reported that patients in the combination arm experienced visual acuity improvements and macular edema reductions over a 3-month period compared to patients in the control arm.

“Based on the fact that so few patients in the Tanzanite combination arm received retreatment, and cognizant of the substantial unmet need associated with frequent office visits and injections required in this patient population, our team conducted an extended evaluation to better assess the duration of effect of the combination treatment and the potential to reduce the burden of therapy,” president & CEO Daniel White said in prepared remarks.

In the company’s Extension study, Clearside evaluated the durability of suprachoroidal CLS-TA in combination with intravitreal Eylea for the 6 months following the Tanzanite trial.

Patients with RVO who participated in the Tanzanite trial and did not receive additional Eylea treatment during the 3-month trial period were eligible to participate in the Extension trial.

In the preliminary analysis of the Extension trial, 17 of the 23 patients in the combination arm of the Tanzanite trial did not receive additional treatment over the 9-month period compared to 4 of the 23 patients in the Eylea arm.

“As RVO is one of the most aggressive retinal vascular diseases that can lead to vision impairment and potential permanent vision loss, there is a strong need to develop new treatment approaches that are both effective and more durable,” Dr.Charles Wykoff said. “While further study is needed, the data from the Tanzanite trial and the Extension Study imply that suprachoroidal CLS-TA in combination with intravitreal Eylea may result in improvements in vision seen as early as month 1 and maintained through month 3, as well as a substantial prolongation of treatment interval. Further research is needed to fully establish the potential clinical benefit of this therapeutic approach. To that end, Clearside launched the 1st of 2 planned Phase III RVO clinical trials, known as Sapphire, in the 1st quarter of 2017.”

“We are encouraged by these data, which suggest that suprachoroidal CLS-TA in combination with intravitreal Eylea for the treatment of RVO in treatment-naïve patients has the potential to not only provide better vision and a faster onset of action, but also, based on the extension study, to lower the need for retreatment when compared to intravitreal Eylea monotherapy,” White added.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: Clearside Biomedical

IN CASE YOU MISSED IT

  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS